Cronos Group (CRON) Stock Price, News & Analysis

Company Overview

Cronos Group Inc. (NASDAQ: CRON) is a global cannabinoid company dedicated to building disruptive consumer brands and advancing cannabis research and development. Since its incorporation in 2016 and public listing in 2018, the company has focused on the cultivation, manufacturing and marketing of cannabis products for both medical and adult-use markets. Cronos Group operates modern production facilities featuring cutting-edge greenhouse technology and indoor cultivation sites, ensuring consistent quality and scalability across its product lines.

The company’s portfolio includes a range of branded products such as Peace Naturals, which offers cannabis oils and capsules for medical patients, and Spinach™, a line of flower and pre-rolled offerings designed for adult-use consumers. In addition to plant-based products, Cronos Group is pioneering synthetic cannabinoids through its Cronos Fermentation™ platform, leveraging proprietary biosynthesis technology to produce rare cannabinoids like CBG and CBDV. This blend of traditional cultivation and fermentation research positions the company at the forefront of innovation in the cannabinoid sector.

Cronos Group’s operations span Canada, Australia and Israel, supported by international export agreements and strategic partnerships. Its primary cultivation facility in Ontario utilizes a temperature- and light-controlled greenhouse, while R&D activities in Israel foster new product formulations and therapeutic applications. The company’s Australian subsidiary holds a license for medicinal cannabis research and manufacturing, enabling access to emerging markets in the Asia-Pacific region.

Leadership at Cronos Group is headed by CEO Michael Gorenstein, who joined the company in 2017 with a background in consumer packaged goods. Under his guidance, Cronos Group secured a strategic equity investment from Altria Group, Inc., which holds a significant stake and provides expertise in regulatory compliance, distribution channels and marketing. This combination of experienced management, strategic partnerships and R&D-driven growth underscores Cronos Group’s commitment to long-term value creation in the evolving cannabis industry.

Key Stats

• Today's Range: $2.01 to $2.07
• 50-Day Range: $1.85 to $2.14
• 52-Week Range: $1.60 to $2.54
• Volume: 812,345 shs
• Average Volume: 1.36 million shs
• Market Capitalization: $779.07 million
• P/E Ratio: 15.54
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Cronos Group Stock Analysis - MarketRank™

Cronos Group scored higher than 32% of companies evaluated by MarketBeat, and ranked 777th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Cronos Group.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cronos Group are expected to grow in the coming year, from ($0.03) to $0.03 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cronos Group is 15.54, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.61.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cronos Group is 15.54, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.57.

Price to Book Value per Share Ratio

Cronos Group has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.43% of the float of Cronos Group has been sold short.

Short Interest Ratio / Days to Cover

Cronos Group has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cronos Group has recently decreased by 1.38%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cronos Group does not currently pay a dividend.

Dividend Growth

Cronos Group does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.43% of the float of Cronos Group has been sold short.

Short Interest Ratio / Days to Cover

Cronos Group has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cronos Group has recently decreased by 1.38%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.79

News Sentiment

Cronos Group has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.97 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Cronos Group this week, compared to 2 articles on an average week.

Search Interest

Only 5 people have searched for CRON on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Cronos Group to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cronos Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.90% of the stock of Cronos Group is held by insiders.

Percentage Held by Institutions

Only 8.71% of the stock of Cronos Group is held by institutions.

CRON Stock Analysis - Frequently Asked Questions

How have CRON shares performed this year?

Cronos Group's stock was trading at $2.02 at the beginning of 2025. Since then, CRON stock has increased by 0.0% and is now trading at $2.02.

How were Cronos Group's earnings last quarter?

Cronos Group Inc. (NASDAQ:CRON) posted its quarterly earnings results on Thursday, May, 8th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.01 by $0.01. The business had revenue of $33.62 million for the quarter, compared to the consensus estimate of $45.44 million. Cronos Group had a negative trailing twelve-month return on equity of 0.07% and a net margin of 39.69%.
Read the conference call transcript.

Who are Cronos Group's major shareholders?

Cronos Group's top institutional investors include Public Employees Retirement System of Ohio (0.02%).
View institutional ownership trends.

How do I buy shares of Cronos Group?

Shares of CRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cronos Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cronos Group investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/15/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRON
• CIK: 1656472
• Web: www.thecronosgroup.com
• Phone: (416) 504-0004
• Fax: N/A
• Employees: 450
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $0.13
• Trailing P/E Ratio: 15.54
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $41.08 million
• Net Margins: 39.69%
• Pretax Margin: 37.64%
• Return on Equity: -0.07%
• Return on Assets: -0.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 27.80
• Quick Ratio: 26.75

Sales & Book Value

• Annual Sales: $117.61 million
• Price / Sales: 6.62
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.90 per share
• Price / Book: 0.70

Miscellaneous

• Outstanding Shares: 385,680,000
• Free Float: 359,070,000
• Market Cap: $779.07 million
• Optionable: Optionable
• Beta: 1.03